Aaron Wealth Advisors LLC Lowers Position in Boston Scientific Corporation $BSX

Aaron Wealth Advisors LLC decreased its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 49.5% in the 1st quarter, Holdings Channel.com reports. The institutional investor owned 12,709 shares of the medical equipment provider’s stock after selling 12,451 shares during the period. Aaron Wealth Advisors LLC’s holdings in Boston Scientific were worth $797,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in BSX. Norges Bank purchased a new stake in shares of Boston Scientific in the 4th quarter valued at about $2,199,395,000. Assenagon Asset Management S.A. increased its holdings in shares of Boston Scientific by 133.6% in the 1st quarter. Assenagon Asset Management S.A. now owns 10,057,936 shares of the medical equipment provider’s stock worth $631,135,000 after buying an additional 5,751,760 shares during the last quarter. Egerton Capital UK LLP raised its position in shares of Boston Scientific by 223.7% during the 3rd quarter. Egerton Capital UK LLP now owns 5,312,504 shares of the medical equipment provider’s stock valued at $518,660,000 after buying an additional 3,671,548 shares in the last quarter. Maverick Capital Ltd. purchased a new stake in shares of Boston Scientific during the 4th quarter valued at $280,735,000. Finally, Farallon Capital Management LLC grew its position in Boston Scientific by 56.7% in the fourth quarter. Farallon Capital Management LLC now owns 7,439,564 shares of the medical equipment provider’s stock worth $709,362,000 after acquiring an additional 2,693,007 shares in the last quarter. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms have weighed in on BSX. Wells Fargo & Company restated an “equal weight” rating and set a $55.00 price target (down from $75.00) on shares of Boston Scientific in a research report on Thursday, May 28th. Barclays cut their target price on shares of Boston Scientific from $96.00 to $89.00 and set an “overweight” rating on the stock in a research note on Thursday, May 28th. Piper Sandler reaffirmed an “overweight” rating and set a $65.00 price objective on shares of Boston Scientific in a research report on Friday, June 12th. Wolfe Research downgraded Boston Scientific from an “outperform” rating to a “peer perform” rating in a report on Friday, May 29th. Finally, Canaccord Genuity Group decreased their target price on Boston Scientific from $71.00 to $70.00 and set a “buy” rating for the company in a research report on Monday, June 1st. One analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $83.36.

Insider Transactions at Boston Scientific

In related news, Director Cheryl Pegus purchased 1,770 shares of the company’s stock in a transaction dated Wednesday, May 20th. The shares were purchased at an average cost of $56.49 per share, with a total value of $99,987.30. Following the transaction, the director directly owned 1,770 shares in the company, valued at $99,987.30. This trade represents a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director David C. Habiger purchased 2,250 shares of the business’s stock in a transaction that occurred on Wednesday, May 20th. The stock was bought at an average price of $55.92 per share, for a total transaction of $125,820.00. Following the purchase, the director directly owned 13,878 shares in the company, valued at $776,057.76. The trade was a 19.35% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have purchased a total of 9,800 shares of company stock valued at $554,012 in the last ninety days. 0.34% of the stock is currently owned by corporate insiders.

Boston Scientific Stock Down 0.1%

Shares of Boston Scientific stock opened at $44.16 on Friday. Boston Scientific Corporation has a 1 year low of $43.89 and a 1 year high of $109.50. The firm has a market cap of $65.64 billion, a price-to-earnings ratio of 18.48, a PEG ratio of 0.85 and a beta of 0.56. The company has a 50-day moving average of $52.87 and a 200 day moving average of $71.13. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.90 and a quick ratio of 1.22.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, topping the consensus estimate of $0.79 by $0.01. The business had revenue of $5.20 billion for the quarter, compared to analyst estimates of $5.19 billion. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. Boston Scientific’s quarterly revenue was up 11.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.75 earnings per share. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. As a group, sell-side analysts anticipate that Boston Scientific Corporation will post 3.36 earnings per share for the current fiscal year.

Boston Scientific declared that its board has initiated a stock repurchase program on Monday, May 18th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the medical equipment provider to buy up to 6.4% of its shares through open market purchases. Shares repurchase programs are generally an indication that the company’s board of directors believes its shares are undervalued.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.